Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Is It Too Late To Buy Clinuvel Pharmaceuticals (CUV) Shares?

Clinuvel Pharmaceuticals Limited (ASX: CUV) shares are up nearly 90% year-to-date and 200% over the last 12 months. Is it too late to buy?

About Clinuvel

Clinuvel Pharmaceuticals is a global biopharmaceuticals company with a focus on developing and delivering treatments for patients with a range of severe genetic and skin disorders. Clinuvel’s main product is called SCENESSE, which they develop and self-distribute.

Why Is The Share Price Rising?

Clinuvel has released plenty of positive news for shareholders over the last 12 months.

In February, Clinuvel released their half-year report for the period ended 31st December 2018. The report showed net profit growth of 189% over the second half of 2017, while revenue was up 27%.

Earnings per share (EPS) increased 188% and the company has no debt on the balance sheet.

No debt, increasing revenue and high margins would all be large contributors to the recent share price growth.

In June, Clinuvel also announced their addition to the S&P/ASX 200 (INDEXASX: XJO) index, meaning they are among the largest 200 companies in Australia. Being in the ASX 200 would also put Clinuvel on the radar of large investment funds and superannuation funds, possibly opening the company up to stronger institutional investment.

Is There More Room For Growth?

Clinuvel has demonstrated an impressive growth rate for revenue and it’s always encouraging to see improving margins.

However, Clinuvel shares already look relatively expensive. Clinuvel shares currently trade on a price-earnings (PE) ratio of 100x, which is lower than some other health companies like Pro Medicus Limited (ASX: PME) and Nanosonics Ltd (ASX: NAN) but still far above what most would call a “conservative” PE ratio. You can read about PE ratios here.

It’s a similar story looking at the price-sales (PS) ratio which is around 67x for Clinuvel, 76x for Pro Medicus and 26.6x for Nanosonics.

Although these ratios have plenty of limitations, they suggest that Clinuvel is very much priced like a growth share. In other words, if you think Pro Medicus and Nanosonics are overpriced right now, there’s a good chance Clinuvel shares are overpriced as well. You can read more about Pro Medicus’ valuation here or read about Nanosonics’ valuation here.

While I like the look of Clinuvel, I’m not buying at today’s price levels.

I’m more interested in the growth shares mentioned in the free report below.

[ls_content_block id=”14947″ para=”paragraphs”]

Disclosure: At the time of writing, Max does not own shares in any of the companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report — or get it emailed to you — for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content